NCT06422663Completed
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 500 (actual)
- First submitted
- 19 Mar 2024
- Start date
- 22 Mar 2024
- Primary completion date
- 13 Mar 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT06422663
What you commit to
- Study type: Observational
- Participants enrolled: 500
- From 22 Mar 2024 to the primary completion date, 13 Mar 2025
- 31 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of chronic obstructive pulmonary disease (COPD) or other clinically relevant chronic respiratory disease other than asthma
- Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrolment. (Once enrolled in the PRESENT Study, patients should not enrol in any investigational trials.)
- Disease or condition other than asthma that requires treatment with systemic or oral steroids
Other illness
- Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
Other
- Patients with poor inhaler skills and adherence
Who the study is looking for
- Physician-confirmed asthma diagnosis with documented evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests)
- Written informed consent
- Moderate-to-severe asthma, which is defined as asthma patients with maintenance. treatment of GINA Step 3-5.
- Age 12 years old and above
Age in the registry: 12 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (31)
Sites in registry order. Save your city in your profile to sort them by distance.
Related publications
- Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT).Ther Adv Respir Dis · 2026 · PMID 42601061
This page is information, not medical advice. Discuss any trial with your doctor.